Journal Article

Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma

Crispin, Max, Savva, Constantinos, Birts, Charles N., Lefas, Alicia, Schapira, Aron, Krishnan, Jamie, Ashton-Key, Margaret, Blaydes, Jeremy P., Copson, Ellen, Laversin, Stéphanie A., Beers, Stephen A., Johnson, Peter W. M., Cutress, Ramsey I.

2022

Overview

Obesity can initiate, promote, and maintain systemic inflammation via metabolic reprogramming of macrophages that encircle adipocytes, termed crown-like structures (CLS). In breast cancer the presence of CLS has been correlated to high body mass index (BMI), larger mammary adipocyte size and postmenopausal status. However, the prognostic significance of CLS in HER2 + breast cancer is still unknown. We investigated the prognostic significance of CLS in a cohort of 69 trastuzumab-naïve and 117 adjuvant trastuzumab-treated patients with primary HER2 + breast cancer. Immunohistochemistry of tumour blocks was performed for CLS and correlated to clinical outcomes. CLS were more commonly found at the adipose-tumour border (B-CLS) (64.8% of patients). The presence of multiple B-CLS was associated with reduced time to metastatic disease (TMD) in trastuzumab treated patients with BMI ≥ 25 kg/m 2 but not those with BMI < 25 kg/m 2 . Phenotypic analysis showed the presence of CD32B + B-CLS was strongly correlated to BMI ≥ 25 kg/m 2 and reduced TMD in trastuzumab treated patients. Multivariable analysis suggested that CD32B + B-CLS positive tumours are associated with shorter TMD in trastuzumab-treated patients (HR 4.2 [95%CI, (1.01–17.4). This study indicates adipose-tumour border crown-like structures that are CD32B + potentially represent a biomarker for improved personalisation of treatment in HER2-overexpressed breast cancer patients.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 631/67/1347 / 631/67/580 / Adipocytes / Adipose Tissue - metabolism / Body mass index / Breast - pathology / Breast cancer / Breast carcinoma / Breast Neoplasms - pathology / ErbB-2 protein / Female / Humanities and Social Sciences / Humans / Immunohistochemistry / Invasiveness / Macrophages / Metastases / Monoclonal antibodies / multidisciplinary / Patients / Post-menopause / Prognosis / Receptor, ErbB-2 - metabolism / Science / Science (multidisciplinary) / Targeted cancer therapy / Trastuzumab / Trastuzumab - metabolism / Trastuzumab - therapeutic use / Tumors